ODI Pharma (ODI) Q2 2026 earnings summary

Executive summary

• Achieved strong revenue growth in Q2 2025/2026, with net sales of SEK 10.9 million, up from SEK 0 in the prior year’s quarter and up 84% sequentially from Q1 2025/2026.

• Returned to profitability in Q2, with profit after financial items of SEK 1.3 million versus a loss of SEK -2.6 million in the prior year.

• Six-month net sales reached SEK 16.9 million, with profit after financial items of SEK 1.26 million, both significantly improved year-over-year.

• Operational stability, improved logistics, and increased order volumes contributed to financial strength and market share gains in Eastern Europe.

Financial highlights

• Q2 net sales: SEK 10,932,119 (0 prior year); six months: SEK 16,900,262 (-4,965 prior year).

• Q2 profit after financial items: SEK 1,298,597 (-2,562,520 prior year); six months: SEK 1,255,378 (-3,953,290 prior year).

• Earnings per share for six months: SEK 0.07 (-0.25 prior year).

• Group solidity at 19% as of December 31, 2025, up from 7% a year earlier.

• Cash flow from operations in Q2: SEK 1,984,285 (-1,560,867 prior year).

Outlook and guidance

• Additional deliveries scheduled for Q3, with continued commercial momentum expected.

• Expansion opportunities being assessed in regulated European medical cannabis markets.

• Growth in demand for medical cannabis products anticipated, especially in Poland and Eastern Europe.